Amgen Inc. kicked off the trading day on 08/14/19 with a price decrease of -3.52%, equivalent to -$7.25 relative change for the day. Taking a more long-term approach, AMGN had a 52-week range of $166.30 to $211.90. At the time of this article’s publishing, this stock is trading at $198.87 after starting the trading session at $202.81. Moving on, the stock has demonstrated a 52-week change amounting to -9.64, alongside an S&P500 52-Week Change of -15.27. At the time of writing, this stock’s 50-day Moving Average stands at $182.08, while the 200-day Moving Average of this stock is currently $186.38.
Currently, this company’s share volume is sitting at $4,484,059, but has maintained average daily volume of $3.04M. This stock has generated an average Year to Date volume of $3.06 million, alongside an average 20-day volume of $3.85 million. This publicly-traded company’s shares outstanding now amounts to $607.00 million, simultaneously with a float of $598.45 million. The organization now has a market capitalization sitting at $120.71 billion.
Amgen Inc.(AMGN) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Amgen Inc.’s current insider ownership accounts for 0.20%, in contrast to 81.50% institutional ownership. According to the most recent latest insider trade that took place on Aug 07 this organization’s Director exercised an option 2,000 at the rate of 54.71, making the entire transaction hit 109,420 in total value, affecting insider ownership by 16,336. Preceding that transaction, on Aug 07 Company’s Director sold 425 at a price of 183.04, making the whole transaction’s value amount to 77,792. This particular insider is now the holder of 5,838 in total.
If we take a glance at the Ownership summary of Amgen Inc.’s stock, 1,978 Institutional holders make up 78.94% of its total stock ownership. All together, they are the legal holders of 473,397,051 shares, which are valued at about $97,576,600,152 in total. If we focus on the top 3 stockholders for this publicly-traded organization, VANGUARD GROUP INC owns 49.39 million shares, with BLACKROCK INC. in 2nd place owning 47.72 million shares and CAPITAL RESEARCH GLOBAL INVESTORS in third place with total ownership of 33.39 million shares.
Amgen Inc. (AMGN) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on Jun-19, the organization reported $3.97 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at $3.59) by $0.38.
The corporation racked up revenue of $5,557.00million for the previous financial quarter, compared to the mean analyst estimate of $5,544.12 million. This company achieved a net margin of 33.77 while generating a return on equity of 62.78. Amgen Inc.’s full-quarter revenue decreased by -3.1%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.49 per share during the current fiscal year.
Amgen Inc.’s EPS increase for this current 12-month fiscal period is 14.80%, and is forecasted to reach 5.54% in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by 5.56% through the next 5 years, which can be compared against the 13.70% growth it accomplished over the previous five years trading on the market.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Amgen Inc., this organization’s Quick Ratio in the last reported quarter now stands at 2.60. The company has managed to achieve an average true range (ATR) of 5.70. Alongside those, its PE Ratio stands at $15.75, and its Beta score is 1.16.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.12 for this organization. Similarly, its price to free cash flow for trailing twelve months is now 21.56. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 11.19, whereas its price to cash per share for the last quarter landed at 35.85.
In the same vein, AMGN’s Diluted EPS (Earnings per Share) trailing twelve month was posted at 12.63, a figure that is expected to reach 3.48 in the next reported quarter, and analysts expect it will be 5.54% at the market close of one year from today’s date.